天津发展：力生制药中期归母净利润净利润3.43亿元 同比增加235.04%

Core Viewpoint - Tianjin Development (00882) reported financial results for its indirect non-wholly-owned subsidiary Tianjin Lisheng Pharmaceutical (002393) for the six months ending June 30, 2025, showing a mixed performance with a decline in revenue but a significant increase in net profit [1] Financial Performance - Total revenue for the period was 732 million RMB, representing a year-on-year decrease of 1.76% [1] - Net profit attributable to the parent company was 343 million RMB, reflecting a substantial year-on-year increase of 235.04% [1] - Basic earnings per share stood at 1.33 RMB [1]